Introduction

ETM

Experimental and Therapeutic Medicine

1792-0981 1792-1015

D.A. Spandidos

10.3892/etm.2017.5331

ETM-0-0-5331

Articles

Combination treatment with quercetin and resveratrol attenuates high fat diet-induced obesity and associated inflammation in rats via the AMPKα1/SIRT1 signaling pathway

Zhao

1 * Cen

Fang

1 * Tian

Feng

2 * Li

Min-Jie

2 Zhang

2 Shen

Hong-Yi

3 Shen

Xiang-Chun

4 Zhou

Ming-Mei

1 Du

Jun

1Center for Chinese Medicine Therapy and Systems Biology, Interdisciplinary Science Research Institute, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China 2Nutrilite Health Institute, Shanghai 201203, P.R. China 3Research Center for Health and Nutrition, School of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China 4The High Educational Key Laboratory of Guizhou for Natural Medicinal Pharmacology and Drugability, School of Pharmaceutical Science, Guizhou Medical University, Huaxi, Guizhou 550025, P.R. China

Correspondence to: Professor Ming-Mei Zhou, Center for Chinese Medicine Therapy and Systems Biology, Interdisciplinary Science Research Institute, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, P.R. China, E-mail: zhoumm368@163.com Dr Jun Du, Nutrilite Health Institute, 720-6 Cailun Road, Pudong, Shanghai 201203, P.R. China, E-mail: eric.du@amway.com *

Contributed equally

12 2017

18 10 2017

14 6 5942 5948 03022017 27072017

2017

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Diet-induced obesity is associated with systemic inflammation, which is considered to originate predominantly from the adipose tissue. Quercetin and resveratrol are two dietary polyphenols that exhibit anti-inflammatory properties and anti-insulin resistance when administered in isolation or combination (CQR). It remains unknown whether CQR reduces high fat diet (HFD)-induced obesity and inflammation in rats. In the current study, 46 male Wistar rats were divided into two groups, one of which was fed a normal diet (ND, 5.4% fat, w/w) and one of which was fed a HFD (45% fat, w/w) for 3 weeks. Following removal of the 12 most obesity-resistant rats from the HFD group, the remaining rats were divided into two sub-groups: A HFD group and a HFD+CQR group (administered 120 mg/kg/day resveratrol and 240 mg/kg/day quercetin). The results revealed that the HFD+CQR group had significantly lower body weights at 11 weeks compared with the HFD group and had significantly reduced visceral adipose tissue weights and adipocyte sizes. Serum lipid profiles were also significantly ameliorated in the HFD+CQR group. CQR attenuated the expression of systemic proinflammatory adipokines, including leptin, tumor necrosis factor-α, monocyte chemoattractant protein-1 and interleukin-6. It also reduced the recruitment of mast cells to the epididyotic adipose tissue (EAT). Furthermore, CQR reversed the HFD-induced suppression of 5′-adenosine monophosphate-activated protein kinase α1 (AMPKα1) phosphorylation and sirtuin 1 (SIRT1) expression in EAT. In conclusion, CQR may suppress obesity and associated inflammation via the AMPKα1/SIRT1 signaling pathway in rats fed a HFD.

quercetin resveratrol high-fat diet inflammation 5′-adenosine monophosphate-activated protein kinase catalytic subunit α-1 sirtuin 1

Introduction

Obesity-induced systemic inflammation originates in adipose tissue prior to hepatic tissue (1,2). The human body contains various fat deposits, which can be divided into white and brown fat. White adipose tissue (WAT) is a multifunctional organ that stores nutrients in the form of fat droplets. In addition, WAT secretes cytokines that affect the body's metabolic state, thus it is sometimes regarded as the largest endocrine organ in the body (3). Excessive energy intake induces adipocyte hypertrophy and hyperplasia, which may lead to the development of high fat diet-induced obesity. Hypertrophic adipocytes release chemokines and proinflammatory cytokines to activate and attract inflammatory cells into WAT. This contributes to systemic insulin resistance and ultimately, a state of chronic low-grade adipose tissue inflammation (4). Polyphenol intake is positively associated with a decrease in the incidence of metabolic and obesity-associated disorders. Quercetin is a polyphenolic flavonoid compound present in a variety of fruits and vegetables, including onions, broccoli, tomatoes, apples and berries. It has a wide range of biological activities and health-promoting effects, including anti-carcinogenic (5), antiviral (6), antioxidant (7), antidiabetic (8), anti-inflammatory (9), anti-aging (10) and angioprotective properties (11). Furthermore, it has recently been suggested that quercetin exerts anti-obesity activity via the mitogen-activated protein kinase (MAPK) and 5′-adenine monophosphate-activated protein kinase α1 (AMPKα1) signaling pathways (12). Resveratrol, a phytoalexin found in the skin and seeds of grapes and in red wine, may also protect against diet-induced obesity and metabolic diseases including hepatic steatosis and insulin resistance (13). In the present study, the effect of combination treatment with quercetin and resveratrol (CQR) was investigated in rats fed a HFD. The impact on CQR on HFD-induced fat accumulation, insulin resistance, proinflammatory cytokine levels, mast infiltration and AMPKα1/sirtuin 1 (SIRT1) signaling in adipose tissues was assessed.

Materials and methods <sec> <title>Animals

The present study was approved by the Institutional Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine (Shanghai, China), and all procedures were performed in accordance with the National Institute of Health's guidelines (14). A total of 46 male 8-week-old Wistar rats with a mean weight of 200±10 g were provided by the Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). Rats were raised in an environment of 22±0.5°C and 40–70% relative humidity under a 12 h light/dark cycle, with food and water freely available. Following 1-week habituation, the rats were randomly divided into 2 groups. The normal diet (ND) group, (n=10) were fed a regular chow diet containing 5.4% fat and the HFD group, (n=36) were fed a HFD containing 45% fat. After 3 weeks, rats in the HFD group were ranked according to weight gain, and rats in the lower third (n=12) were excluded from the study as they were deemed to be obesity resistant. The remaining 24 rats in the HFD group were randomly divided into 2 sub-groups: i) A HFD group (n=12); and ii) a HFD+CQR (n=12) group. CQR treatment consisted of 120 mg/kg/day resveratrol (purity, ≥98%; Hangzhou Great Forest Biomedical Co., Ltd., Hangzhou, China) and 240 mg/kg/day quercetin (purity ≥98; Nanjing Zelang Medical Technology Co., Ltd., Nanjing, China) The body weight and food intake of the rats was recorded each week. After 11 weeks, rats were anesthetized with isoflurane and sacrificed following a 12 h fast. Blood was extracted from the abdominal aorta and centrifuged at 5,000 × g for 15 min at 4°C. The serum was separated and stored at −80°C prior to analysis. Following blood collection, subcutaneous adipose tissues (SATs), epididymis adipose tissues (EATs) and perinephric adipose tissues were promptly removed, rinsed, weighed on ice and then snap frozen in liquid nitrogen and stored at −80°C.

Biochemical parameters

Total cholesterol (C), triglycerides (TG), high-density lipoprotein-C (HDL-C) and low-density lipoprotein-C (LDL-C) in the serum were measured and quantified using a Hitachi 7600 automatic biochemical analyzer (Hitachi, Ltd., Tokyo, Japan) with the corresponding kits as follows: Quick Auto Neo T-CHOLII assay reagent and Quick Auto Neo TGII assay reagent, manufactured by Shino-Test Corporation (Tokyo, Japan); L-type HDL-C reagent 1 (cat no. 998-09011), reagent 2 (cat no. 994-09111); and L-type LDL-C reagent 1 (cat no. 997-39893) and reagent 2, (cat no. 993-39993), manufactured by Wako Pure Chemical Industries, Ltd. (Osaka, Japan).

Cytokine quantification

Levels of leptin, adiponectin, insulin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and monocyte chemotactic protein-1 (MCP-1) in the serum were quantified using the corresponding commercial rat ELISA kits as follows: Rat leptin, LEP ELISA kit (cat no. CSB-E07433r); rat adiponectin, ADP ELISA kit, (cat no. CSB-E07271r); rat insulin, INS ELISA kit (CSB-E05070r); rat IL-6, IL-6 ELISA kit (cat no. CSB-E04640r); rat TNF-α ELISA kit (cat no. CSB-E11987r); and rat MCP-1/monocyte chemotactic and activating factor, MCP-1/MCAF ELISA kit (cat no. CSB-E07429r; Cusabio Biotech Co., Ltd., Wuhan, China) according to the manufacturer's protocols.

Histopathology

Adipose tissues were collected at 11 weeks and fixed in 4% formalin at room temperature for 24 h, embedded in paraffin and sliced serially into sections 5-µm thick. To determine adipocyte size, hematoxylin and eosin staining was conducted on EATs at room temperature for 30 min. Five visual fields were randomly selected from each section with an Olympus BX51 light microscope (Olympus Corporation, Tokyo, Japan) and examined using Image-Pro Plus version 6.0 (Media Cybernetics, Inc., Rockville, MD, USA) to determine the average adipocyte diameter. Toluidine blue staining was also performed on EATs for 1 h by briefly submerging tissue sections in 0.1% aqueous toluidine blue (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at room temperature, the histological images were used to quantify the number of mast cells present, as previously described (15). Mast cell numbers were counted using a light microscope and were presented as cell numbers/mm².

Protein extraction and western blot analysis

Plasma membrane proteins were extracted from adipose tissues using a radioimmunoprecipitation assay lysis buffer (cat no. 89900, Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA), total protease inhibitor and phosphatase inhibitor, as described previously (16). Protein concentration was measured using a commercial bicinchoninic acid assay kit and a microplate reader at 570 nm. Subsequently protein (40 µg/lane) was separated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked with 2% bovine serum albumin (cat no. K720; Ameresco, Inc., Framingham, MA, USA) at room temperature and TBS with Tween-20 for 1 h, then incubated overnight at 4°C with AMPKα1 antibody (cat no. 2795), phosphorylated (p)-AMPKα1 (Thr172; cat no. 2535), or SIRT1 rabbit monoclonal antibodies (cat no 3931). Membranes were also incubated with monoclonal mouse anti-human β-actin antibody (cat no. 4967; all 1:1,000 dilution; all from Cell Signalling Technology, Inc., Danvers, MA, USA) as the loading control. Following extensive washing in Tween-PBS, membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G antibody (1:4,000; cat no. sc-2030; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 1 h. Bands were visualized using LightShift™ Chemiluminescent electrophoretic mobility shift assay kit (cat no. 20148; Thermo Fisher Scientific, Inc.) and the ImageQuant™ LAS 4000 Mini, quantified using ImageQuant TL 7.0 software (both from GE Healthcare, Chicago, IL, USA) and expressed as the ratio of pAMPKα1 to AMPKα1 or SIRT1 to β-actin.

Statistical analysis

All data are presented as the mean ± standard error of the mean. For multiple comparisons, differences were analyzed using one-way analysis of variance followed by Tukey's multiple comparison test. P<0.05 was considered to indicate a statistically significant difference. All statistics were analyzed using Graphpad Prism version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA).

Results <sec> <title>Treatment with CQR results in a lower body and visceral adipose tissue weight in an HFD-rat model

After 3 weeks, at the point of CQR intervention, the body weight of rats in the HFD group was significantly higher than those in the ND group (Fig. 1A). The body weight increase was alleviated by CQR between weeks 8 and 11 and following 11 weeks intervention; HFD+CQR rats had a significantly lower body weight than HFD rats (Fig. 1A). Food intake was significantly lower in HFD rats compared with ND rats (Fig. 1B), however energy intake was significantly higher (Fig. 1C). CQR did not exert a marked effect on food and energy intake. At the end of week 11, HFD+CQR rats had a notably lower visceral (epididymal and perirenal) adipose tissue weight (Fig. 1D) and a significantly smaller adipose cell diameter compared with the HFD group (Fig. 1E and F). Subcutaneous adipose tissue weight did not differ significantly across all groups (Fig. 1D). These results suggest that CQR treatment may inhibit HFD-induced obesity.

CQR treatment affects lipid levels in the serum

The HFD group exhibited significantly higher levels of total C, TG and LDL-C in the serum compared with the ND group (Table I). CQR significantly attenuated these lipid levels compared with the HFD. However, CQR did not reverse the decrease in serum HDL-C induced by HFD (Table I).

CQR treatment reduces insulin and leptin levels in serum

HFD significantly elevated serum insulin and leptin levels but lowered the serum adipinectin levels compared with the ND (Table I). CQR significantly decreased serum insulin and leptin levels but exhibited no significant effect on serum adipinectin compared with the HFD group.

CQR suppresses the clustering of mast cells in adipose tissue

During the formation of HFD induced-obesity and exacerbation of adipose tissue inflammation or insulin resistance, a large amount of mast cells infiltrate the adipose tissue (17). It was reported that HFD induced mast cell clustering in WAT and promoted obesity and insulin resistance (18), while quercetin suppresses the release of cytokines from mast cells in vitro and obesity mice (16,19). The number of mast cells in EAT was calculated to evaluate the effects of CQR on mast cell in adipose tissue of HFD-induced rats (Fig. 2). The results demonstrated that HFD significantly promoted the transition of mast cells into EATs, while CQR significantly reversed this effect (both P<0.05).

CQR suppresses proinflammatory cytokines

A variety of proinflammatory cytokines are secreted by hypertrophic adipocytes and cause inflammatory cell infiltration during the development and progression of obesity (20). Several important proinflammatory cytokines involved in insulin resistance were detected in this study; results from ELISA determined that levels of the proinflammatory cytokines TNF-α, IL-6 and MCP-1, which increased in rats on a HFD, were significantly suppressed by CQR (Table I). These results suggest that CQR may relieve systematic inflammation induced by obesity.

CQR upregulates the AMPKα1/SIRT1 signalling pathway

AMPKα1 and SIRT1 are two key nutrient sensors linking nutrient metabolism and inflammation (21–22). AMPKα1 negatively regulates lipid-induced inflammation, which acts through SIRT1 to protect against obesity, inflammation and insulin resistance (23). It has been demonstrated that quercetin alleviates obesity-associated adipose tissue macrophage infiltration and inflammation in mice via the AMPKα1/SIRT1 signaling pathway (16). Resveratrol also induces beneficial effects on obesity and metabolic disturbances by activating the AMPKα1/SIRT1 signaling pathway (24). Consistent with previous studies, AMPKα1 phosphorylation (Fig. 3A) and SIRT1 expression (Fig. 3B) in the EAT of rats fed a HFD were significantly suppressed. Treatment with CQR significantly reversed the suppression of AMPKα1 phosphorylation in a rat model (Fig. 3A).

Discussion

Quercetin and resveratrol are two types of dietary polyphenols, which may have beneficial effects on metabolic syndrome (25–33). It has also been reported that quercetin and resveratrol have a therapeutic effect on triacylglycerol metabolism in WAT (25). The results of the present study suggest that the combination of quercetin and resveratrol ameliorate insulin resistance and adipose tissue inflammation in obese rats. Furthermore, CQR treatment was able to reverse the changes in AMPKα1 phosphorylation and SIRT1 expression that occur in adipose tissues. To the best of our knowledge, the current study is the first to demonstrate that CQR has synergic effects on body fat accumulation and adipose inflammation by activating the AMPKα1/SIRT1 signaling pathway.

Previous studies have demonstrated that resveratrol and quercetin may reduce body fat accumulation in animal models (26–31). In our previous study, CQR exhibited synergistic effects on a HFD-induced metabolic phenotype in mice (32). Since polyphenols are efficient, particularly at higher doses (33), doses of 120 mg/kg/day resveratrol and 240 mg/kg/day quercetin were used in the current study. These are similar to the doses used in other comparable studies performed in rodents (31,34–36). The recommended dosage of quercetin and resveratrol in obesity or insulin-resistance studies remains controversial and it was reported that treatment with lower doses of resveratrol may activate SIRT1, whereas higher doses activate AMPK in a SIRT1-independent manner (37). The doses of quercetin and resveratrol used in some studies are 30 mg/kg/day and 15 mg/kg/day, respectively (26,38). In addition, quercetin is considered to be safe as it does not induce carcinogenicity and genotoxicity following oral administration at high doses (up to 2,000 mg/kg) (39). Lagouge et al (31) demonstrated that dietary treatment with 200 or 400 mg/kg/day resveratrol, delivered in either chow or a HFD, significantly increased the aerobic capacity and resistance to HFD induced-obesity in mice.

The anti-obesity effects of quercetin and resveratrol on HFD-induced body weight gain remain controversial and negative results have been reported by several research groups (40–42). Similar to previous studies (24,26,29,32,43), the results of the present study demonstrated that the body weight gain between weeks 9 and 11 in rats fed a HFD and treated with CQR was significantly attenuated compared with rats fed a HFD alone. Treatment with CQR also reduced the weights of renal adipose tissues and EATs, however it did not affect SAT weight or food and energy intake. CQR therefore appears to have a mild weight-reducing and visceral fat-reducing effect. Visceral adipose tissue is a proinflammatory endocrine tissue and may be responsible for the increased cardiometabolic risk that occurs as body mass index rises (44). Regardless of adiposity status, visceral adiposity is associated with an adverse cardiometabolic profile, including inflammation, insulin resistance and myocardial dysfunction, all of which are hallmarks of an ‘obese’ phenotype (44). In addition the current study demonstrated that, HFD-induced dyslipidemia caused an increase in total C, TGs and LDL-C and a decrease in HDL-C in the blood. Chaudhari et al (45) also reported that a HFD induced significant increases in total C, TG and LDL-C in the rat serum, whereas it reduced HDL-C in rat serum (41). In the present study, CQR treatment increased serum HDL-C and decreased serum TC, TG and LDL-C, demonstrating that CQR is able to reduce the effects of a HFD in a rat model of obesity, which is consistent with previous reports (12,46–48).

Chronic low-grade adipose tissue inflammation serves an important role in the development of HFD-induced obesity and insulin resistance (4,49,50). The proinflammatory or anti-inflammatory molecules abnormally secreted from obese adipose tissue are called adipokines and provide evidence that there is a direct association between obesity and systemic inflammation (51). The adipose tissue of obese individuals exhibits increased expression of proinflammatory adipokines, including TNF-α, MCP-1 and IL-6 but a reduced expression of adiponectin (52). Systemic leptin is increased in animals fed a HFD or with inflammation and/or infection states and directly affects cytokine production (53); thus it was hypothesized that CQR may ameliorate the inflammation in adipose tissue induced by a HFD. The results of the current study demonstrated that CQR attenuates adipocyte growth in EAT and mast cell clustering into adipose tissues. In the serum, CQR treatment reduced leptin, as well as TNF-α, MCP-1 and IL-6 levels.

To reveal the molecular mechanisms by which CQR attenuates obesity associated adipose tissue inflammation, two important nutrient sensors and inflammatory regulators in EAT were assessed in the current study; AMPKα1 and SIRT1 (54,55). CQR significantly increased HFD-suppressed AMPKα1 phosphorylation and markedly increased SIRT1 expression in EATs, suggesting that CQR influences the AMPKα1/SIRT1 signaling pathway in adipose tissues. The AMPKα1/SIRT1 signaling pathway may be a novel cellular target due to its anti-inflammatory effects in adipocytes (24,56). AMPKα1 activates SIRT1 and inhibits inflammation in macrophages (57); furthermore, AMPKα1 may inhibit the activation of the nuclear factor-κB system, a key regulator of innate immunity and inflammation (55). Activation of AMPKα1 may suppress the synthesis of pro-inflammatory cytokines, such as IL-6 and IL-8, in adipocytes (58). Aminoimidazole-4-carboxami-deriboside, a pharmacological activator of AMPKα1, may inhibit inflammatory responses via AMPKα1-independent pathways, and reverse lipopolysaccharide and HFD-induced inflammation (55–59). Reduction of EAT SIRT1 expression may induce ectopic inflammatory gene expression and the overexpression of SIRT1 inhibits HFD-induced increases in inflammation in adipose tissue (60). Dong et al (16) reported that dietary quercetin suppressed adipose tissue macrophage infiltration and inflammation via the AMPKα1/SIRT1 pathway in mice fed a HFD. Furthermore, Bitterman and Chung (61) reported that the AMPKα1/SIRT1 signaling pathway is the primary target for the metabolic effects of resveratrol.

In conclusion, the results of the present study suggest that CQR ameliorates not only excessive body weight gain and dyslipidemia, but also adipose tissue inflammation in rats with HFD-induced obesity. The anti-obese effect of CQR is associated with a reduction in body weight gain, adipocyte diameter, adipose tissue weight and an improvement of dyslipidemia in serum. Its anti-obese effect is closely associated with its anti-inflammation effects by which it reduces adipokine secretion and activates the AMPKα1/SIRT1 signaling pathway. These results indicate that CQR has the potential to reduce HFD-induced obesity and inflammation.

Acknowledgements

The present study was supported by the Education Department of Guizhou Province 1 (grant no. 2014-31), the Scientific and Technologic Innovated Team of Guizhou Province 2 (grant no. 2015-4025), the High-level Innovation Talents 3 (grant no. 2015-4029), the Teacher Development Project of Shanghai Municipal Education Commission and the Innovation Project of Amway (China) Research and Development Center Ltd., Co.

References 1

Wensveen

Valentić

Šestan

Turk

Wensveen T

Polić

The ‘Big Bang’ in obese fat: Events initiating obesity-induced adipose tissue inflammation

Eur J Immunol45244624562015

10.1002/eji.201545502

26220361

van der Heijden

Sheedfar

Morrison

Hommelberg

Kor

Kloosterhuis

Gruben

Youssef

de Bruin

Hofker

High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice

Aging (Albany NY)72562682015

10.18632/aging.100738

25979814

Ronti

Lupattelli

Mannarino

The endocrine function of adipose tissue: An update

Clin Endocrinol (Oxf)643553652006

16584505

Ouchi

Parker

Lugus

Walsh

Adipokines in inflammation and metabolic disease

Nat Rev Immunol1185972011

10.1038/nri2921

21252989

Brito

Ribeiro

Abrantes

Pires

Teixo

Tralhão

Botelho

Quercetin in cancer treatment, alone or in combination with conventional therapeutics?

Curr Med Chem22302530392015

10.2174/0929867322666150812145435

26264923

Chiow

Phoon

Putti

Tan

Chow

Evaluation of antiviral activities of Houttuynia cordata Thunb. Extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection

Asian Pac J Trop Med9172016

10.1016/j.apjtm.2015.12.002

26851778

Boots

Haenen

Bast

Health effects of quercetin: From antioxidant to nutraceutical

Eur J Pharmacol5853253272008

10.1016/j.ejphar.2008.03.008

18417116

Eid

Haddad

The antidiabetic potential of quercetin: Underlying mechanisms

Curr Med Chem243553642017

10.2174/0929867323666160909153707

27633685

Yao

Han

Yang

Chaudhry

Wang

Liu

Yin

Quercetin, inflammation and immunity

Nutrients81672016

10.3390/nu8030167

26999194

Corrêa

RCG

Peralta

Haminiuk

CWI

Maciel

Bracht

Ferreira

ICFR

New phytochemicals as potential human anti-aging compounds: Reality, promise, and challenges

Crit Rev Food Sci Nutr131162016

10.1080/10408398.2016.1233860

Pashevin

Tumanovska

Dosenko

Nagibin

Gurianova

Moibenko

Antiatherogenic effect of quercetin is mediated by proteasome inhibition in the aorta and circulating leukocytes

Pharmacol Rep63100910182011

10.1016/S1734-1140(11)70617-X

22001989

Nabavi

Russo

Daglia

Nabavi

Role of quercetin as an alternative for obesity treatment: You are what you eat!

Food Chem1793053102015

10.1016/j.foodchem.2015.02.006

25722169

Aguirre

Fernández-Quintela

Arias

Portillo

Resveratrol: Anti-obesity mechanisms of action

Molecules1918632186552014

10.3390/molecules191118632

25405284

National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals8th edition

National Academies Press (US)

Washington, DC

2011

Altintas

Azad

Nayer

Contreras

Zaias

Faul

Reiser

Nayer

Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice

J Lipid Res524804882011

10.1194/jlr.M011338

21148461

Dong

Zhang

Bian

Bao

Liu

Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: A mechanism including AMPKα1/SIRT1

J Lipid Res553633742014

10.1194/jlr.M038786

24465016

Sun

Kersten

Mechanisms of inflamatory responses in obese adipose tissue

Annu Rev Nutr322612862012

10.1146/annurev-nutr-071811-150623

22404118

Liu

Divoux

Sun

Zhang

Clément

Glickman

Sukhova

Wolters

Gorgun

Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice

Nat Med159409452009

10.1038/nm.1994

19633655

Park

Lee

Son

Park

Kim

Choi

Singh

Lee

Kim

Flavonoids inhibit histamine release and expression of proinfl ammatory cytokines in mast cells

Arch Pharm Res31130313112008

10.1007/s12272-001-2110-5

18958421

Lee

Lin

Chen

Lin

Liang

Osthole enhances glucose uptake through activation of AMP-activated protein kinase in skeletal muscle cells

J Agric Food Chem5912874128812011

10.1021/jf2036559

22098542

Sag

Carling

Stout

Suttles

Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype

J Immunol181863386412008

10.4049/jimmunol.181.12.8633

19050283

Yoshizaki

Milne

Imamura

Schenk

Sonoda

Babendure

Smith

Jirousek

Olefsky

SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes

Mol Cell Biol29136313742009

10.1128/MCB.00705-08

19103747

Yang

Kahn

Shi

Xue

Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1

J Biol Chem28519051190592010

10.1074/jbc.M110.123620

20421294

De Ligt

Timmers

Schrauwen

Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?

Biochim Biophys Acta1852113711442015

10.1016/j.bbadis.2014.11.012

25446988

Arias

Macarulla

Aguirre

Milton

Portillo

The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue

Eur J Nutr553413482016

10.1007/s00394-015-0854-9

25669932

Gómez-Zorita

Fernández-Quintela

Macarulla

Aguirre

Hijona

Bujanda

Milagro

Martínez

Portillo

Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress

Br J Nutr1072022102012

10.1017/S0007114511002753

21733326

Rivera

Morón

Sánchez

Zarzuelo

Galisteo

Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats

Obesity Silver (Spring)16208120872008

10.1038/oby.2008.315

18551111

Jung

Cho

Ahn

Jeon

Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes

Phytother Res271391432013

10.1002/ptr.4687

22447684

Kobori

Masumoto

Akimoto

Oike

Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice

Mol Nutr Food Res555305402011

10.1002/mnfr.201000392

21462320

Alberdi

Rodríguez

Miranda

Macarulla

Arias

Andrés-Lacueva

Portillo

Changes in white adipose tissue metabolism induced by resveratrol in rats

Nutr Metab (Lond)8292011

10.1186/1743-7075-8-29

21569266

Lagouge

Argmann

Gerhart-Hines

Meziane

Lerin

Daussin

Messadeq

Milne

Lambert

Elliott

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

Cell127110911222006

10.1016/j.cell.2006.11.013

17112576

Zhou

Wang

Zhao

Wang

Fan

Yang

Liao

Bao

Zhao

Zhang

Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice

J Proteome Res11496149712012

10.1021/pr3004826

22916952

Amiot

Riva

Vinet

Effects of dietary polyphenols on metabolic syndrome features in humans: A systematic review

Obes Rev175735862016

10.1111/obr.12409

27079631

Andrade

Frade

Guimarães

Freitas

Lopes

Guimarães

de Paula

Coimbra

Santos

Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet

Eur J Nutr53150315102014

10.1007/s00394-014-0655-6

24468941

Zhao

Lyv

Feng

Fang

Maternal quercetin administration during gestation and lactation decrease endoplasmic reticulum stress and related inflammation in the adult offspring of obese female rats

Eur J Nutr53166916832014

10.1007/s00394-014-0673-4

24570028

Liu

Guo

Chu

Heart protective effects and mechanism of quercetin preconditioning on anti-myocardial ischemia reperfusion (IR) injuries in rats

Gene5451491552014

10.1016/j.gene.2014.04.043

24769323

Price

Gomes

Ling

Duarte

Martin-Montalvo

North

Agarwal

Ramadori

Teodoro

SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function

Cell Metab156756902012

10.1016/j.cmet.2012.04.003

22560220

Arias

Macarulla

Aguirre

Miranda

Portillo

Liver delipidating effect of a combination of resveratrol and quercetin in rats fed an obesogenic diet

J Physiol Biochem715695762015

10.1007/s13105-015-0403-2

25827944

Harwood

Danielewska-Nikiel

Borzelleca

Flamm

Williams

Lines

A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties

Food Chem Toxicol45217922052007

10.1016/j.fct.2007.05.015

17698276

Panchal

Poudyal

Brown

Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats

J Nutr142102610322012

10.3945/jn.111.157263

22535755

Boesch-Saadatmandi

Wagner

Wolffram

Rimbach

Effect of quercetin on inflammatory gene expression in mice liver in vivo-role of redox factor 1, miRNA-122 and miRNA-125b

Pharmacol Res655235302012

10.1016/j.phrs.2012.02.007

22402395

Pan

Ren

Zhu

Zheng

Fan

Wang

Liu

Resveratrol increases nephrin and podocin expression and alleviates renal damage in rats fed a high-fat diet

Nutrients6261926312014

10.3390/nu6072619

25025298

Peredo-Escárcega

Guarner-Lans

Pérez-Torres

Ortega-Ocampo

Carreón-Torres

Castrejón-Tellez

Díaz-Díaz

Rubio-Ruiz

The combination of resveratrol and quercetin attenuates metabolic syndrome in rats by modifying the serum fatty acid composition and by upregulating SIRT1 and SIRT2 expression in white adipose tissue

Evid Based Complement Alternat Med20154740322015

10.1155/2015/474032

26609312

Bays

Adiposopathy is ‘sick fat’ a cardiovascular disease?

J Am Coll Cardiol57246124732011

10.1016/j.jacc.2011.02.038

21679848

Chaudhari

Bhandari

Khanna

Preventive effect of embelin from embelia ribes on lipid metabolism and oxidative stress in high-fat diet-induced obesity in rats

Planta Med786516572012

10.1055/s-0031-1298379

22450777

Franco

Lisboa

Lima

Amaral

Peixoto-Silva

Resende

Oliveira

Passos

Moura

Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning

J Nutr Biochem249609662013

10.1016/j.jnutbio.2012.06.019

22959054

Baek

Chung

Lee

D'Souza

Jeon

Kim

Kweon

Hong

Treatment of obesity with the resveratrol-enriched rice DJ-526

Sci Rep438792014

10.1038/srep03879

24464364

D'Andrea

Quercetin: A flavonol with multifaceted therapeutic applications?

Fitoterapia1062562712015

10.1016/j.fitote.2015.09.018

26393898

Sun

Kersten

Mechanisms of inflammatory responses in obese adipose tissue

Annu Rev Nutr322612862012

10.1146/annurev-nutr-071811-150623

22404118

Osborn

Olefsky

The cellular and signaling networks linking the immune system and metabolism in disease

Nat Med183633742012

10.1038/nm.2627

22395709

Berg

Scherer

Adipose tissue, inflammation, and cardiovascular disease

Circ Res139399492005

10.1161/01.RES.0000163635.62927.34

Weisberg

McCann

Desai

Rosenbaum

Leibel

Ferrante

Obesity is associated with macrophage accumulation in adipose tissue

J Clin Investig112179618082003

10.1172/JCI200319246

14679176

Fantuzzi

Faggioni

Leptin in the regulation of immunity, inflammation, and hematopoiesis

J Leukoc Biol684374462000

11037963

Weng

Schuppan

AMPK regulates macrophage polarization in adipose tissue inflammation and NASH

J Hepatol586196212013

10.1016/j.jhep.2012.09.031

23046670

Salminen

Hyttinen

Kaarniranta

AMP-activated protein kinase inhibits NF-κB signaling and inflammation: Impact on healthspan and lifespan

J Mol Med (Berl)896676762011

10.1007/s00109-011-0748-0

21431325

Jeon

Lee

Lim

Brown Alga Ecklonia cava polyphenol extract ameliorates hepatic lipogenesis, oxidative stress, and inflammation by activation of AMPK and SIRT1 in high-fat diet-induced obese mice

J Agric Food Chem633493592015

10.1021/jf502830b

25479240

Yang

Kahn

Shi

Xue

Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1

J Biol Chem28519051190592011

10.1074/jbc.M110.123620

Grisouard

Dembinski

Mayer

Keller

Müller

Christ-Crain

Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation

Diabetol Metab Syndr3162011

10.1186/1758-5996-3-16

21774820

Łabuzek

Liber

Gabryel

Okopień

AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) increases the production of toxic molecules and affects the profile of cytokines release in LPS-stimulated rat primary microglial cultures

Neurotoxicology311341462010

10.1016/j.neuro.2009.10.006

19853624

Gillum

Kotas

Erion

Kursawe

Chatterjee

Nead

Muise

Hsiao

Frederick

Yonemitsu

SirT1 regulates adipose tissue inflammation

Diabetes60323532452011

10.2337/db11-0616

22110092

Bitterman

Chung

Metabolic effects of resveratrol: Addressing the controversies

Cell Mol Life Sci72147314882015

10.1007/s00018-014-1808-8

25548801

Figure 1.

Treatment with CQR reduces the body and visceral fat weights of rats fed a HFD. Rats were fed a ND, a HFD or a HFD+CQR for a period of 11 weeks. Subsequently (A) body weight, (B) food intake, (C) energy intake and (D) white adipose tissue weights were measured. (E) EAT morphology was observed using a light microscope at a magnification of ×200 and the (F) adipocyte diameters in EAT were measured. Data are expressed as the mean ± standard error of mean. *P<0.05, **P<0.01 and ***P<0.001 vs. ND. ^#P<0.05 and ^###P<0.001 vs. HFD. CQR, combination of quercetin and resveratrol; HFD, high fat diet; ND, normal diet; EAT, epididymal adipose tissues.

Figure 2.

Treatment with CQR reduces the clustering of mast cells in the epididymal adipose tissue (EAT). At 11 weeks, tissue samples were collected and (A) epididymal white adipose tissue was observed using a light microscope (small box: magnification, ×200, big box: magnification, ×100) following toluidine blue staining of the mast cells indicated by the blue stain. Pink plaques are erythrocytes and leukocytes in the blood vessels of EAT. Erythrocytes are cells without a nucleus, while leukocytes are cells with a nucleus. (B) Quantification of mast cells in the indicated groups was performed by observing the slides, n=8 per group. *P<0.05 and ^#P<0.05. All data are presented as the mean ± standard error of mean. CQR, combination of quercetin and resveratrol; HFD, high fat diet; ND, normal diet.

Figure 3.

Treatment with CQR increases AMPKα1 phosphorylation and SIRT1 expression in the EAT of rats fed a HFD. After 11 weeks, tissue samples were obtained from each group and the (A) protein and phosphorylation levels of AMPKα1 and (B) the protein expression of SIRT1 in EATs, were measured. Quantification of AMPKα1 activity and SIRT1 expression was presented as the ratio of pAMPKα1 to total AMPKα1 and SIRT1 to β-actin, respectively. Statistical differences between groups were identified using a one-way ANOVA test followed by Tukey's multiple comparison test (n=8 per group). All data are presented as the mean ± standard error of mean. ***P<0.001 and ^#P<0.05. AMPKα1, 5′-adenosine monophosphate-activated protein kinase α1; SIRT1, sirtuin 1; EAT, epididymal adipose tissue; HFD, high fat diet; ND, normal diet; CQR, combination of quercetin and resveratrol; p, phosphorylated.

Table I.

CQR normalizes the concentrations of serum constituents in HFD fed rats.

Parameter	ND	HFD	HFD+CQR
Serum total C (µmol/l)	1536±101.5^a	1987±100.6	1587±70.36^a
Serum TG (µmol/l)	685.8±89.93^c	1366±129.3	746.4±80.98^c
Serum HDL-C (µmol/l)	1010±24.72^b	778.3±30.79	901.7±23.09
Serum LDL-C (µmol/l)	275.0±13.76^b	462.5±29.39	305.0±31.66^b
Serum insulin (IU/ml)	66.66±4.422^a	84.65±4.917	68.16±3.454^a
Serum leptin (pg/ml)	542.5±27.07^c	904.2±47.88	667.7±36.90^c
Serum adiponectin (pg/ml)	68.78±4.889^a	38.74±3.740	60.70±3.934
Serum TNF-α (pg/ml)	41.50±6.000^b	71.28±3.545	50.34±5.403^a
Serum IL-6 (pg/ml)	1.141±0.0871^b	2.063±0.2744	1.131±0.0842^b
Serum MCP-1 (pg/ml)	47.56±5.594^a	72.47±3.848	49.01±4.671^a

Statistical differences between groups were identified using a one-way ANOVA test followed by Tukey's multiple comparison test, n=12 per group. All data in the table are presented as the mean ± standard error of mean.

P<0.05

P<0.01

P<0.001, vs. the HFD model group. C, cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; MCP-1, monocyte chemotactic protein-1; ND, normal diet; HFD, high fat diet; CQR, combination of quercetin and resveratrol.